MEMO

From	*To* Consultant Chest Physician i/c
Ref. *in*	*(Attn.:* Statistics Unit, Wanchai Chest Clinic *)*
Tel. No.	*Your Ref.* *in*
Fax. No.	*dated* *Fax. No.* 25728921
Date	*Total Pages*

Notification of case to RR/MDR-TB Registry at Wanchai Chest Clinic

I would like to notify a case of rifampicin-resistant TB (RR-TB), with/ without* bacillary resistance to isoniazid, as follows:

Name:

Sex *: M [0] / F [1] **DOB** (dd/mm/yyyy): / /

HKID / Passport / Travel document number *:

Ethnicity *: Chinese / Asians (pl specify:_____) / Others: _____

Residence *: Permanent / New immigrant (in HK< 7 yrs) / Imported worker/ Tourist (2-way permit /other*) / Illegal immigrant / Unknown

Chest clinic /Hospital admission /HA clinic number *:

Site of RR/MDR-TB* : Pulmonary [1] / Extrapulmonary (EP) [2] / Both [3] (Specify EP site:)

Pretreatment phenotypic drug susceptibility testing results:

	(S) [0]	(R) [1]		(S) [0]	(R) [1]
H (Isoniazid)	□	□	E (Ethambutol)	□	□
R (Rifampicin)	□	□	S (Streptomycin)	□	□

Baseline results of molecular tests for resistance-associated mutations:

Isoniazid	*inhA*: no data □ present□ absent □	*katG*: no data □ present□ absent□
Rifampicin	*rpoB*: no data □ present □ absent □	

HIV status*: -ve [0] / +ve [1] / not checked [9] / status cannot be disclosed

Past TB Rx >=1 month prior to development of RR/MDR-TB*: N [0] / Y [1] / unknown [9]

Date of start of second line treatment (dd/mm/yyyy): / /

Use of drugs (Circle one or more as appropriate)

a.	Linezolid	f.	Fluoroquinolones	(Drug name: _____)
b.	Delamanid	g.	Injectables	(Drug name: _____)
c.	Bedaquiline	h.	Pretomanid	
d.	Clofazimine	i.	Other 2nd line drugs	(_____)
e.	Cycloserine	j.	Not applicable	

Case referred to Chest Clinic (name):

(if applicable): Chest Hospital/ others (name):

Remarks:

Signature:

Name of doctor:

**Circle as appropriate*

Notes:

1. Please enclose a copy of the laboratory drug susceptibility report and/or molecular ST report(s).

2 A copy of this form should preferably be filed in the patient's medical record for future reference.